CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Washington, District of Columbia, United States and 73 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Baltimore, Maryland, United States and 20 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Lutherville, Maryland, United States and 75 other locations
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatmen...
Phase 2
Baltimore, Maryland, United States
B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-ce...
Phase 4
Baltimore, Maryland, United States
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
Vienna, Virginia, United States and 5 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Lutherville, Maryland, United States and 36 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
Baltimore, Maryland, United States and 121 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Baltimore, Maryland, United States and 122 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Washington, District of Columbia, United States and 35 other locations
Clinical trials
Research sites
Resources
Legal